Irish AI start-up targets chemotherapy bottlenecks with remote assessment platform
The company, a spin-out from Trinity College Dublin's ADAPT Centre and backed by Enterprise Ireland as a High Potential Start-Up (HPSU), has demonstrated the efficacy of its conversational AI tool in a six-month pilot study conducted in partnership with Health Innovation Hub Ireland (HIHI) and Tallaght University Hospital (TUH).
The platform enables patients to complete chemotherapy toxicity assessments remotely in under six minutes, a process that traditionally requires in-person consultations. According to the study, the tool not only improves patient experience but also delivers measurable gains in clinical efficiency and cost savings.
The study found that, 'For patients, eAltra's pre-appointment remote assessment, completed in under six minutes, reduces unnecessary travel and optimises appointment scheduling – timed chemo production ensures treatment is ready when a patient arrives, eliminating wait times by up to two hours.' Patients reported high satisfaction with the tool's usability and clarity.
Clinical teams also stand to benefit. The study reported a minimum productivity gain of 3.5 hours per treatment day, equating to 20 minutes saved per patient.
Importantly, the AI chatbot achieved a 98 per cent agreement rate with nurse-led assessments, the current gold standard.
Scalable cost-savings
From a financial perspective, the implications are significant. In a hospital treating 200 patients annually, the tool could generate savings of €27,300 per nurse, rising to €55,000 with two clinical nurse specialists. Additional savings are anticipated from reduced paper usage.
The platform is designed for seamless integration with existing health IT infrastructure. It complies with HL7 standards and is interoperable with national systems including the National Cancer Information System, Cerner/Oracle Health, and EPIC.
Sustainability is another key advantage. By enabling remote care, eAltra reduces patient travel and associated emissions. With healthcare accounting for five per cent of global travel, the shift to digital engagement offers a meaningful reduction in carbon footprint.
Denis Roche, founder and CEO of eAltra explained that, 'eAltra is a spin out company of Trinity College Dublin and was awarded High Potential Startup status by Enterprise Ireland.'
Roche explained how, 'Health Innovation Hub Ireland has been supporting our development throughout these milestones. The clinical access, study design support and pilot management they have provided has contributed to our product development and market positioning. We are hugely ambitious for eAltra both at home and abroad and the HIHI pilot result provide significant evidence of efficacy, useability, impact and patient satisfaction.'
AI reshaping healthcare
Eimear Galvin, HIHI Dublin Manager, highlighted how AI is reshaping healthcare She said: 'These study results show that eAltra improves patient care, provides cost savings and increases productivity by streamlining processes and minimising delays in systemic anti-cancer therapy, in this case chemotherapy.'
Galvin added that by enabling remote assessments just 24 hours pre-appointment, unnecessary travel and associated costs are eliminated, ensuring timely rescheduling when required. She explained that, 'Timed chemotherapy production aligns drug preparation with patient arrival, reducing wait times by up to two hours and optimising pharmacy workflows.'
The announcement comes as HIHI launches a national competition, 'HIHI.AI', to identify and pilot AI-driven healthcare innovations.
The call is open to companies, researchers, and clinicians until 28 August, with selected projects to be trialled in clinical settings across Ireland. More information is available at hih.ie.
Digital care policy advances
eAltra's innovation aligns closely with Ireland's national AI strategy. As the Department of Enterprise, Trade and Employment stated in its 2024 strategy refresh: 'AI presents opportunities completely unlike those we have experienced before with previous technological advancements, in terms of their potentially transformative impact for our collective good.'
Ireland's 'Digital for Care' framework also underpins eAltra's approach. The framework sets out a roadmap to digitally transform health services in Ireland and improve access for patients, and at the European level, the European Commission has noted that, 'AI is emerging not just as a tool but as a transformative force reshaping healthcare delivery.'
The Commission has said that 'AI-driven personalised treatment plans can complement traditional approaches by offering more targeted and effective care, improving patient outcomes while also helping to reduce the financial burden on healthcare systems.'
By Brian Maguire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euractiv
3 days ago
- Euractiv
Irish pharma still risks wildcard Section 232 tariffs, despite Trump's trade agreement
Dublin - Ireland's multibillion-euro pharmaceutical industry is still in a precarious position despite this week's US-EU trade deal. The Trump administration's new 15% tariffs haven't settled market nerves, with a sweeping Section 232 national security investigation in play, and official assurances viewed cautiously. Under this week's US-EU trade framework, a 15 per cent tariff will apply to a wide range of European goods entering the US. While both US and EU officials say most pharmaceuticals will attract the 15% tariff, this remains to be seen pending the outcome of the ongoing Section 232 inquiry, which could trigger even steeper duties. With over €58bn of Ireland's €72.6bn in US exports last year stemming from pharmaceuticals, the risk is significant. The industry underpins nearly 50,000 jobs and is central to Ireland's foreign direct investment model. Speaking after the framework was unveiled, Tánaiste Simon Harris said: 'Whilst the agreement between the EU and the US is welcome, we know that the imposition of any tariffs will have implications and that now is the time to intensify efforts to find and secure more markets for Irish businesses and Irish jobs.' Despite assurances from Brussels, uncertainty prevails in Dublin. One senior cabinet minister, speaking on condition of anonymity, told the Irish Independent: 'We're still in the dark about elements of it… Pharma and semiconductors is where a lot of this will rest and there's still an open question about where they'll end up.' Danny McCoy, CEO of Irish business group Ibec, said the trade agreement 'brings an end to a significant amount of uncertainty for some businesses. However, a 15% tariff still represents a substantial burden for many industries.' He added: 'Pharmaceuticals and semiconductors, which equate to 75% of Ireland-US trade, are, we understand, included in the 15% deal. However, there is still a question around the stability of that rate over both the short and long-term in the face of ongoing Section 232 investigations.' 'Tax scam' rhetoric remains While the European Commission insists pharmaceuticals will not face tariffs above the 15 per cent threshold, citing a 'very clear political commitment' from President Trump, the White House has continued to signal its intent to reconfigure pharmaceutical supply chains. A significant part of this uncertainty stems from previous comments by Commerce Secretary Howard Lutnick, who notoriously described Ireland as his favourite 'tax scam', indicating political appetite for deep sector-specific trade actions. With Ireland still potentially in Trump and Lutnick's sights, Ireland's pharma business group, the IPHA, declined to comment on the trade deal and 15% tariff rate. However, it's understood that the IPHA are aligned with the EFPIA, the European Federation of Pharmaceutical Industries and Associations , which represents the interests of companies such as Pfizer, Roche, and Sanofi. EFPIA has warned against US trade measures, saying, 'Tariffs on medicines are a blunt instrument that will disrupt supply chains, impact on investment in research and development, and ultimately harm patient access to medicines on both sides of the Atlantic.' 'If the intent is to secure pharmaceutical investment in research, development and manufacturing, rebalance trade and ensure a fairer distribution of how global pharmaceutical innovation is financed, then there are more effective means than tariffs that would help, rather than hinder, global advances in patient care and economic growth.' The Section 232 wildcard Since returning to the White House, President Trump has launched 13 Section 232 national security investigations. Four have resulted in tariffs - including steel, aluminium, autos, and most recently copper. A decision on pharmaceuticals is required by late December 2025, within the statutory 270-day window from the investigation's launch in April. However, it is thought likely that the investigation team will report within the next three weeks. A White House official told Euractiv on 28 July: 'When the pharma Section 232 tariffs take effect, the EU will only be subject to 15%.' The following day, the administration published a fact sheet stating: 'As part of President Trump's strategy to establish balanced trade, the European Union will pay the United States a tariff rate of 15%, including on autos and auto parts, pharmaceuticals, and semiconductors.' It's been a long week, and the legal ground remains unsettled. Tariff 'stacking' risk Law firm Covington has warned: 'While initial guidance from the Trump administration provided that Section 232 tariffs would not apply simultaneously (or 'stack') on top of certain other types of tariffs … recent changes to these rules have rendered the stacking question more complex.' 'As additional Section 232 tariffs are announced, further changes to the applicable tariff stacking rules are likely.' President Trump's prior use of Section 232 saw duties of 25 per cent on steel and 10 per cent on aluminium, later raised to 50 per cent. In April, he reiterated his intent to target offshore pharmaceutical production, stating: 'We don't make our own drugs […] anymore. The drug companies are in Ireland, in lots of other places – China – and all I have to do is impose a tariff. The more, the faster they move here.' As with Secretary Lutnick's 'tax scam' remarks, there is no indication that President Trump has softened his stance in any way. The EU trade deal requires $600 billion in investments from Europe, over President Trump's term, part of which will be from the pharmaceutical sector. The White House keeps a public list of inward investment 'wins', and the clock is ticking for pharma to reshore. Trade impact and economic risks The US, which imports over 70 per cent of its essential medicines, could face severe domestic consequences. Generics and hospital injectables - accounting for 90 per cent of prescriptions - are particularly exposed. Medicines for Europe, which represents generic drugmakers, warned that tariffs 'would likely exacerbate the existing shortages in the U.S. and would most likely contribute to a huge wave of additional shortages, including for most products in the essential medicines list.' Reuters reports that analysts at ING estimate that a 15 per cent tariff on pharmaceuticals could slash Irish pharma exports to the US by €8.7bn annually, assuming standard price elasticity and no rapid substitution. EU-wide losses could range from €18bn to €22bn, depending on the final scope and duration of tariffs and other trade measures. Analysts estimate that a 15 per cent tariff could increase US drug prices by 5 - 10 per cent, adding up to $30bn annually to healthcare costs - particularly burdening hospitals and lower-income patients. Increasing healthcare costs ahead of mid-term elections and pushing inflation still higher is a high-risk strategy for the White House. Market response Despite the looming threat, equity markets have responded with cautious optimism. Following the deal's announcement, investors seem to believe that mitigation strategies may buffer the blow. Companies are already anticipating the changes. Sanofi recently sold a New Jersey facility to Thermo Fisher to maintain domestic production. Roche is increasing US inventories, while others are locking in new contract manufacturing agreements. The road ahead In Ireland, the government is convening a national Trade Forum tomorrow, Friday, to assess the fallout. Tánaiste Harris described it as '... a timely opportunity to share and gain insights on what this deal will mean for the future of Irish businesses, jobs, and the economy.' Irish industry leaders continue to call for restraint and clarity, warning that missteps in the coming months could have long-term implications not just for European drug exports, but for American patients and hospitals as well. By Brian Maguire
Euractiv
4 days ago
- Euractiv
Ireland's ‘compassionate' justice and mental health strategy aims to avoid prison return
The Irish government has published the second annual progress report of the High-Level Taskforce on Mental Health and Addiction, highlighting a series of cross-departmental initiatives aimed at improving outcomes for individuals with mental health and addiction issues who encounter the criminal justice system. The report, released on 28 July, outlines developments between September 2023 and September 2024, including the national rollout of Mental Health First Aid training to An Garda Síochána (Ireland's police force), the launch of the Community Access Support Team (CAST) pilot in Limerick, and progress on a dual diagnosis service in Cork Prison. Minister for Health Jennifer Carroll MacNeill placed particular emphasis on the need for a compassionate, integrated response. 'The High-Level Taskforce on Mental Health and Addiction recognised the importance of taking a compassionate, whole-person approach to supporting people with mental health and addiction challenges who come into contact with the criminal justice system,' she said. 'Many of the Taskforce's recommendations build on what's already in place, aiming to strengthen the connections between services. This joined-up approach is designed to offer more consistent, meaningful support to individuals navigating both the justice and health systems,' she added. Avoiding incarceration Carroll MacNeill also pointed to the health sector's progress in developing alternatives to incarceration. 'A particular focus has been on creating real, person-centred alternatives through Diversion initiatives, ensuring that care is better integrated and more responsive to the needs of this small but highly vulnerable group,' she noted. The Taskforce, a joint initiative between the Departments of Health and Justice, was established following the publication of its foundational report in 2022. Its Steering Committee includes representatives from the Health Service Executive (HSE), the Irish Prison Service, the Probation Service, and An Garda Síochána. Minister for Justice Jim O'Callaghan welcomed the report's publication, noting that it can help 'reduce the likelihood of future offending.' Minister of State for Mental Health Mary Butler highlighted the expansion of the Central Mental Hospital and the development of Crisis Resolution Teams as key achievements. She also referenced the Mental Health Bill, which concluded its passage through the Dáil on 9 July 2025. The new policing model An Garda Síochána has played a central role in implementing the Taskforce's recommendations, particularly through the CAST pilot in Limerick. The initiative, part of the broader 'Policing Service for the Future' strategy, is designed to support individuals experiencing situational trauma or mental health crises. A Garda spokesperson told Euractiv: 'The Commission on the Future of Policing in Ireland stated that societal-wide issues such as the mental health of individuals are not the responsibility of An Garda Síochána alone… [recommending] the establishment of multi-agency teams (Crisis Intervention Team) that would include Gardaí to respond to the needs of individuals with mental health issues.' The CAST project, a partnership between An Garda Síochána and HSE Mid-West Mental Health Services, exemplifies this inter-agency approach. It is currently being trialled in the Limerick Garda Division. The Gardaí have also embedded mental health awareness into their operational framework. Over 3,500 personnel have received Mental Health First Aid training under a Memorandum of Understanding signed with Mental Health First Aid Ireland in June 2023. In line with the new Policing Model, Gardaí are equipped to respond to critical incidents involving mental health crises. 'There are trained Garda Negotiators, Operational Commanders in every Garda Region throughout the country,' the spokesperson said. 'In recent years, An Garda Síochána has put a significant emphasis on our role as the first line of defence of the human rights of all people we come into contact with.' Ireland's efforts to reform the intersection of mental health, addiction, and the criminal justice system are being significantly underpinned by European Union policy and funding, aligning national priorities with broader EU objectives on public health, social inclusion, and human rights. The strategic and financial support from Brussels has enabled Ireland to advance initiatives such as the High-Level Taskforce on Mental Health and Addiction, which seeks to divert vulnerable individuals away from incarceration and toward integrated care pathways. Convergence with EU priorities Ireland's national mental health strategy, 'Sharing the Vision: A Mental Health Policy for Everyone', is closely aligned with EU-level frameworks, including the EU Health Strategy and the European Pillar of Social Rights. These frameworks advocate for universal access to quality healthcare, with mental health increasingly recognised as a core component of public health policy. Ireland has also tapped into several EU funding streams to support its reform agenda. These include: European Social Fund Plus (ESF+), EU4Health Programme: and the Justice Programme. These funds are being used to scale up initiatives such as the Community Access Support Team (CAST) pilot in Limerick and the national rollout of mental health training for Gardaí. As Ireland continues to embed a more humane and coordinated approach to mental health within its justice system, EU policy and funding remain critical enablers. They are reinforcing the country's commitment to reform while anchoring it within a broader European vision of inclusive, rights-based public health at a time of rising drug use in Ireland and a mental health crisis, particularly amongst young people. By Brian Maguire
Euractiv
4 days ago
- Euractiv
Italian authorities raid Meta over WhatsApp AI function
The Italian Competition Authority (AGCM) has launched an investigation into Meta over the AI function in its WhatsApp messaging service. The authority suspects that Meta abused its dominant position in messaging by pre-installing the AI function without first requiring users to opt in. Officials raided Meta's Italian subsidiary on Tuesday, assisted by antitrust specialists of the Italian Financial Police, AGCM said in a press release. A Commission spokesperson said that its DG COMP was closely cooperating with the Italian competition authorities on the investigation. A Meta spokesperson said that the company was "fully cooperating with the Italian Competition Authority" per an email statement sent to Euractiv. "Offering free access to our AI features in WhatsApp gives millions of Italians the choice to use AI in a place they already know," the spokesperson added. Meta has claimed that the AI option is an entirely optional service to use. However, the Italian competition authorities have said that since March 2025, Meta AI has been pre-install its AI services, "by combining with its WhatsApp service, without any prior request from users," in its statement. The AI service had already come under scrutiny in several European countries. Meta had delayed the rollout of its AI service after the Irish data protection authority raised questions surrounding data use. The data protection watchdog in Hamburg, Germany, also started investigating Meta's use of user data but dropped the case in May. (cp)
